Peter O’Gorman

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution

Suparno Chakrabarti, Stephen Mackinnon, Raj Chopra et al. · Blood · 2002 · 359 citations · Full text

Whole-Body MRI Versus PET in Assessment of Multiple Myeloma Disease Activity

Conor Shortt, Tadhg G. Gleeson, Karen Breen et al. · American Journal of Roentgenology · 2009 · 184 citations

Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI)

Tadhg G. Gleeson, John M. Moriarty, Conor Shortt et al. · Skeletal Radiology · 2008 · 163 citations

Computed Tomography, Engineering, Medical Imaging +13

Protein and chemotherapy profiling of extracellular vesicles harvested from therapeutic induced senescent triple negative breast cancer cells

Emma Kavanagh, Sinéad Lindsay, Melinda Halász et al. · Oncogenesis · 2017 · 102 citations · Full text

Breast Oncology, Nanotherapeutics, Extracellular Microvesicles +20